$NPCUF $NPC.TO Allon Advances Pivotal Neuro-Degenerative Study with Results Expected by Year-End
publication date: Jul 16, 2012
Written by Mike Havrilla--Allon Therapeutics is developing lead product candidate Davunetide as a naturally-derived neuro-protective compound with a summary of an ongoing pivotal study under SPA for a rare degenerative brain disease...
Sorry this page is available to subscribers only. If you're not a subscriber why not join today?
If you are already a subscriber, please login.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site including:
- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database with over 300 events and updated daily
- Members Only Live Interactive Webinars
- Live Chat Room
- Video Lessons / Trade Reviews
- Chart / Technical Analysis
- Run-Up Valuation Studies
- Weekly Watchlist Newsletter
- Email / SMS (Text Message) Alerts of critical news
- Access to view Mark Messier and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Historical FDA Tracker
- Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates
- Direct Email Communication
- Affiliate Program
If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.
